Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 147

Similar articles for PubMed (Select 24321581)

1.

Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.

Zucali PA, Perrino M, Lorenzi E, Ceresoli GL, De Vincenzo F, Simonelli M, Gianoncelli L, De Sanctis R, Giordano L, Santoro A.

Lung Cancer. 2014 Jun;84(3):265-70. doi: 10.1016/j.lungcan.2013.11.011. Epub 2013 Nov 20.

PMID:
24321581
2.
3.

Treatment patterns and survival analysis in 9014 patients with malignant pleural mesothelioma from Belgium, the Netherlands and England.

Damhuis RA, Khakwani A, De Schutter H, Rich AL, Burgers JA, van Meerbeeck JP.

Lung Cancer. 2015 May 22. pii: S0169-5002(15)00250-0. doi: 10.1016/j.lungcan.2015.05.014. [Epub ahead of print]

PMID:
26044908
4.

Mesothelioma treatment.

Parente B.

Rev Port Pneumol. 2008 Jul;14 Suppl 2:S35-S44. doi: 10.1016/S0873-2159(15)30313-5. Review. English, Portuguese.

PMID:
25967566
5.

A Potential Immune Therapy for Mesothelioma.

[No authors listed]

Cancer Discov. 2015 May 8. [Epub ahead of print]

PMID:
25956959
6.

Palliative chemotherapy for gastroesophageal cancer in old and very old patients: A retrospective cohort study at the National Center for Tumor Diseases, Heidelberg.

Berger AK, Zschaebitz S, Komander C, Jäger D, Haag GM.

World J Gastroenterol. 2015 Apr 28;21(16):4911-8. doi: 10.3748/wjg.v21.i16.4911.

7.

Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients.

Buti S, Bordi P, Tiseo M, Bria E, Sperduti I, Di Maio M, Panni S, Novello S, Rapetti SG, Pilotto S, Genestreti G, Rossi A, Pezzuolo D, Camisa R, Tortora G, Ardizzoni A.

Lung Cancer. 2015 Jun;88(3):319-24. doi: 10.1016/j.lungcan.2015.03.016. Epub 2015 Apr 1.

PMID:
25870156
8.

Demographics, management and survival of patients with malignant pleural mesothelioma in the National Lung Cancer Audit in England and Wales.

Beckett P, Edwards J, Fennell D, Hubbard R, Woolhouse I, Peake MD.

Lung Cancer. 2015 Jun;88(3):344-8. doi: 10.1016/j.lungcan.2015.03.005. Epub 2015 Mar 30.

PMID:
25863904
9.

The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experience.

Bambury RM, Benjamin DJ, Chaim JL, Zabor EC, Sullivan J, Garcia-Grossman IR, Regazzi AM, Ostrovnaya I, Apollo A, Xiao H, Voss MH, Iyer G, Bajorin DF, Rosenberg JE.

Oncologist. 2015 May;20(5):508-15. doi: 10.1634/theoncologist.2014-0354. Epub 2015 Apr 6.

PMID:
25845990
10.

A new prognostic index for overall survival in malignant pleural mesothelioma: the rPHS (regimen, PS, histology or stage) index.

Kataoka Y, Yamamoto Y, Otsuki T, Shinomiya M, Terada T, Fukuma S, Yamazaki S, Hirabayashi M, Nakano T, Fukuhara S.

Jpn J Clin Oncol. 2015 Jun;45(6):562-8. doi: 10.1093/jjco/hyv039. Epub 2015 Apr 2.

PMID:
25838292
11.

The efficacy of pemetrexed and bevacizumab intrapleural injection for malignant pleural mesothelioma-mediated malignant pleural effusion.

Chen D, Li X, Zhao H, Fu Y, Yao F, Hu J, Du N.

Indian J Cancer. 2014 Mar;51 Suppl 3:e82-5. doi: 10.4103/0019-509X.154058.

12.

The role of interleukin-6 in malignant mesothelioma.

Abdul Rahim SN, Ho GY, Coward JI.

Transl Lung Cancer Res. 2015 Feb;4(1):55-66. doi: 10.3978/j.issn.2218-6751.2014.07.01. Review.

13.

The South West Area Mesothelioma and Pemetrexed trial: a multicentre prospective observational study evaluating novel markers of chemotherapy response and prognostication.

Hooper CE, Lyburn ID, Searle J, Darby M, Hall T, Hall D, Morley A, White P, Rahman NM, De Winton E, Clive A, Masani V, Arnold DT, Dangoor A, Guglani S, Jankowska P, Lowndes SA, Harvey JE, Braybrooke JP, Maskell NA.

Br J Cancer. 2015 Mar 31;112(7):1175-82. doi: 10.1038/bjc.2015.62.

14.

Persistent lung expansion after pleural talc poudrage in non-surgically resected malignant pleural mesothelioma.

Rena O, Boldorini R, Papalia E, Mezzapelle R, Baietto G, Roncon A, Casadio C.

Ann Thorac Surg. 2015 Apr;99(4):1177-83. doi: 10.1016/j.athoracsur.2014.11.050. Epub 2015 Feb 7.

PMID:
25669666
15.

MDM2 is an important prognostic and predictive factor for platin-pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53.

Walter RF, Mairinger FD, Ting S, Vollbrecht C, Mairinger T, Theegarten D, Christoph DC, Schmid KW, Wohlschlaeger J.

Br J Cancer. 2015 Mar 3;112(5):883-90. doi: 10.1038/bjc.2015.27. Epub 2015 Feb 10.

PMID:
25668009
16.

Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study.

Ghanim B, Klikovits T, Hoda MA, Lang G, Szirtes I, Setinek U, Rozsas A, Renyi-Vamos F, Laszlo V, Grusch M, Filipits M, Scheed A, Jakopovic M, Samarzija M, Brcic L, Stancic-Rokotov D, Kern I, Rozman A, Dekan G, Klepetko W, Berger W, Glasz T, Dome B, Hegedus B.

Br J Cancer. 2015 Mar 3;112(5):783-92. doi: 10.1038/bjc.2015.9. Epub 2015 Jan 29.

PMID:
25633038
17.

SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM).

Ou SH, Moon J, Garland LL, Mack PC, Testa JR, Tsao AS, Wozniak AJ, Gandara DR.

J Thorac Oncol. 2015 Feb;10(2):387-91. doi: 10.1097/JTO.0000000000000360.

PMID:
25611229
18.

Acute lower limb ischemia complicating pemetrexed and carboplatin combination chemotherapy for malignant pleural mesothelioma.

Valerio S, Bracale UM, Giribono AM, Viviani E, Caioni F, del Guercio L.

Ann Ital Chir. 2014 Nov 3;85(ePub). pii: S2239253X14023019.

PMID:
25586574
19.

Third-line chemotherapy with carboplatin, gemcitabine and liposomised doxorubicin for malignant pleural mesothelioma.

de Lima VA, Sørensen JB.

Med Oncol. 2015 Feb;32(2):458. doi: 10.1007/s12032-014-0458-x. Epub 2015 Jan 9.

PMID:
25572813
20.

Detection of circulating tumour cells in peripheral blood of patients with malignant pleural mesothelioma.

Raphael J, Massard C, Gong IY, Farace F, Margery J, Billiot F, Hollebecque A, Besse B, Soria JC, Planchard D.

Cancer Biomark. 2015 Jan 1;15(2):157-62. doi: 10.3233/CBM-140448.

PMID:
25519011
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk